Pharmacokinetics and tissue penetration of ceftolozane-tazobactam in diabetic patients with lower limb infections and healthy adult volunteers

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 12, 2017, Pages

  Monogue, Marguerite L ^a   Stainton, Sean M ^a   Baummer Carr, Arlinda ^a   Shepard, Ashley K ^b   Nugent, James F ^b   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Urology Division Hartford Healthcare Medical Group   (United States)

Author keywords

Ceftolozane tazobactam; Diabetes; Microdialysis; Pharmacokinetics; Tissue penetration

Indexed keywords

CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC PATIENT; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTERIACEAE; EXTRACELLULAR FLUID; FEMALE; HOSPITAL PATIENT; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIMIT OF DETECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TIME TO MAXIMUM PLASMA CONCENTRATION; WOUND INFECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; GRAM NEGATIVE INFECTION; HALF LIFE TIME; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PERMEABILITY;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CEPHALOSPORINS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PERMEABILITY;

EID: 85034738414     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01449-17     Document Type: Article

References (32)

1. Amin N, Doupis J. 2016. Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World J Diabetes 7:153–164. https://doi.org/10.4239/wjd.v7.i7.153.
2. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. 1994. Assessment and management of foot disease in patients with diabetes. N Engl J Med 331:854. https://doi.org/10.1056/NEJM199409293311307.
3. Naves CC. 2016. The diabetic foot: a historical overview and gaps in current treatment. Adv Wound Care (New Rochelle) 5:191–197. https://doi.org/10.1089/wound.2013.0518.
4. Lipsky BA. 2008. New developments in diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 24(Suppl 1):S66–S71. https://doi.org/10.1002/dmrr.828.
5. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. 1999. Incidence, outcomes, and cost of foot ulcers in participants with diabetes. Diabetes Care 22:382–387. https://doi.org/10.2337/diacare.22.3.382.
6. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E, Infectious Diseases Society of America. 2012. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54:e132– e173. https://doi.org/10.1093/cid/cis346.
7. Food and Drug Administration. 2014. Zerbaxa® (ceftolozane/ tazobactam) prescribing information. Food and Drug Administration, Rockville, MD. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf. Accessed 30 May 2017.
8. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, III, Karlowsky JA. 2014. Ceftolozane/tazobactam: a novel cephalosporin/-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74:31–51. https://doi.org/10.1007/s40265-013-0168-2.
9. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother 54: 3427–3431. https://doi.org/10.1128/AAC.01753-09.
10. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 56:3086–3091. https://doi.org/10.1128/AAC.06349-11.
11. Aiudi A, Miller B, Krishna G, Adedoyin A, Xiao A. 2016. Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects. Fundam Clin Pharmacol 30:625–633. https://doi.org/10.1111/fcp.12227.
12. Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. 2016. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy 36: e30–e33. https://doi.org/10.1002/phar.1744.
13. Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. 2012. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/ tazobactam in healthy adult subjects. J Antimicrob Chemother 67: 2463–2469. https://doi.org/10.1093/jac/dks246.
14. Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G. 2015. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol 55:230–239. https://doi.org/10.1002/jcph.395.
15. Kuti JL, Ghazi IM, Quintiliani R, Jr, Shore E, Nicolau DP. 2016. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/ tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 48:342–343. https://doi.org/10.1016/j.ijantimicag.2016.06.005.
16. Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL. 2016. Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation. Antimicrob Agents Chemother 60:6578–6584. https://doi.org/10 .1128/AAC.01566-16.
17. Blot SI, Pea F, Lipman J. 2014. The effect of pathophysiology on pharmacokinetics in the critically ill patient— concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3–11. https://doi.org/10.1016/j.addr.2014.07.006.
18. Melchers MJ, Mavridou E, Seyedmousavi S, van Mil AC, Lagarde C, Mouton JW. 2015. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Antimicrob Agents Chemother 59:3373–3376. https://doi.org/10.1128/AAC.04402-14.
19. Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. 2013. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother 57:5679–5683. https://doi.org/10.1128/AAC.01348-13.
20. So W, Kuti JL, Shepard A, Nugent J, Nicolau DP. 2016. Tissue penetration and exposure of cefepime in patients with diabetic foot infections. Int J Antimicrob Agents 47:247–248. https://doi.org/10.1016/j.ijantimicag.2016.01.002.
21. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum -lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57:1577–1582. https://doi.org/10.1128/AAC.01590-12.
22. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phe-notypically diverse Gram-negative organisms. Antimicrob Agents Chemother 56:544 –549. https://doi.org/10.1128/AAC.01752-10.
23. Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D. 2014. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 58:6311– 6314. https://doi.org/10.1128/AAC.03572-14.
24. European Committee on Antimicrobial Susceptibility Testing. 2016. Clinical breakpoints— bacterial (v6.0). http://www.eucast.org/clinical_breakpoints. Accessed 30 May 2017.
25. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of -lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 57:5924–5930. https://doi.org/10.1128/AAC.00656-13.
27. Lagacé-Wiens P, Rubinstein E. 2012. Adverse reactions to -lactam antimicrobials. Expert Opin Drug Saf 11:381–399. https://doi.org/10.1517/14740338.2012.643866.
28. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. https://doi.org/10.1159/000180580.
29. Müller M, Haag O, Burgdorff T, Georgopoulos A, Weninger W, Jansen B, Stanek G, Pehamberger H, Agneter E, Eichler HG. 1996. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis. Antimicrob Agents Chemother 40:2703–2709.
30. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. 2011. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother 55:4170–4175. https://doi.org/10.1128/AAC.00445-11.
31. Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP. 2010. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 54:5209–5213. https://doi.org/10.1128/AAC.01051-10.
32. Sutherland C, Nicolau DP. 2016. Development of an HPLC method for the determination of ceftolozane/tazobactam in biological and aqueous matrixes. J Chromatogr Sci 54:1037–1040. https://doi.org/10.1093/chromsci/bmw047.